Research and Commercialization of Graphene

If you had never heard of "graphene" a few days ago, you might know something about it today - if you follow the Nobel Prize announcements. Two physicists at the University of Manchester (UK) were awarded the Nobel Prize in Physics "for groundbreaking experiments regarding the two-dimensional material graphene," carbon flakes that are only as thick as a single atom yet as strong as steel and as conductive as copper.

But, what happens next for this revolutionary nanoscale material? Two social scientists began a study earlier in 2010 to understand the as yet undeveloped pathway to the commercialization of graphene - the processes, plans, promises and perils. Team leaders with the Center for Nanotechnology in Society at Arizona State University (CNS-ASU), Jan Youtie at Georgia Institute of Technology (Georgia Tech) and Philip Shapira at the University of Manchester and Georgia Tech are in the throes of their project on the Comparative Research and Innovation Approaches of Graphene Centers.

Graphene is anticipated to have potential applications in electronics to build semiconductors beyond the limits of silicon-based technology. It also offers promising applications for higher performance solar cells, LCD screens and photon sensors. Now that graphene has been identified and found to be stable in ultra-thin sheets, research efforts to understand it more thoroughly and to produce it in large quantities have ballooned. Yet, graphene is still at the development stage, and its commercialization pathway remains to be determined.

To kick-off their work on graphene innovation, Youtie and Shapira have been undertaking field work in two of the world's leading centers for graphene development: the University of Manchester and Georgia Tech. As acknowledged by the Nobel Committee for Physics when it awarded its 2010 Prize to Manchester physicists Andre Geim and Konstantin Novoselov, Manchester is the site of seminal work on graphene, including the first laboratory production of graphene sheets. Georgia Tech is the site of a National Science Foundation-funded Materials Science and Engineering Center (MRSEC) focused on research and development on epitaxial graphene. Youtie's and Shapira's project seeks to understand similarities and differences in the plans, programs and approaches to commercialize graphene-related applications in both locations. This includes examination of both the strategies for research and development and those for fostering commercialization in terms of external partnerships in the metropolitan regions of Manchester and Atlanta, elsewhere in the country, and internationally. In addition to field work, Youtie and Shapira also are undertaking analyses of publications, patents, funding, and corporate activities in graphene.

Over the coming year, Youtie and Shapira plan to expand their research focus to other locations in the United States and around the world where graphene research and commercialization clusters are emerging. Although graphene's full impacts may take many years to materialize, the results of Youtie's and Shapira's research will provide real-time insights to researchers, companies, policymakers and other stakeholders keen to understand how research in specific nanotechnology domains moves into early applications, what barriers and concerns are raised, and how these are being addressed.

Youtie's and Shapira's pilot project has received travel funding from a UK-US Collaboration Development Award (CDA) of the British Embassy and British Consulates in the United States, with supplementary support through CNS-ASU and the Manchester Institute for Innovation Research.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.